Calamos Wealth Management LLC Sells 1,950 Shares of Stryker Corporation $SYK

Calamos Wealth Management LLC lessened its holdings in Stryker Corporation (NYSE:SYK) by 4.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 41,892 shares of the medical technology company’s stock after selling 1,950 shares during the period. Calamos Wealth Management LLC’s holdings in Stryker were worth $11,537,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Community Bank & Trust Waco Texas lifted its stake in Stryker by 2.3% in the 2nd quarter. Community Bank & Trust Waco Texas now owns 1,395 shares of the medical technology company’s stock worth $439,000 after acquiring an additional 31 shares in the last quarter. Cornerstone Financial Management LLC boosted its position in Stryker by 66.0% during the 2nd quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company’s stock worth $25,000 after acquiring an additional 31 shares during the period. NWF Advisory Services Inc. boosted its position in Stryker by 2.3% during the 2nd quarter. NWF Advisory Services Inc. now owns 1,472 shares of the medical technology company’s stock worth $463,000 after acquiring an additional 33 shares during the period. Harold Davidson & Associates Inc. grew its stake in Stryker by 0.4% during the 1st quarter. Harold Davidson & Associates Inc. now owns 8,668 shares of the medical technology company’s stock valued at $2,848,000 after acquiring an additional 34 shares in the last quarter. Finally, Private Harbour Investment Management & Counsel LLC grew its stake in Stryker by 0.9% during the 2nd quarter. Private Harbour Investment Management & Counsel LLC now owns 3,927 shares of the medical technology company’s stock valued at $1,236,000 after acquiring an additional 34 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Citizens Jmp dropped their target price on Stryker from $400.00 to $390.00 and set a “market outperform” rating on the stock in a report on Friday, October 30th. Jefferies Financial Group decreased their price target on shares of Stryker from $440.00 to $405.00 and set a “buy” rating for the company in a report on Tuesday, September 22nd. Deutsche Bank Aktiengesellschaft lowered their price objective on shares of Stryker from $315.00 to $275.00 and set a “hold” rating on the stock in a research report on Friday, October 30th. JPMorgan Chase & Co. dropped their price objective on shares of Stryker from $350.00 to $340.00 and set an “overweight” rating on the stock in a research note on Friday, October 30th. Finally, Evercore increased their target price on shares of Stryker from $335.00 to $355.00 in a research report on Wednesday, October 28th. Twenty-one analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $343.73.

Insider Activity at Stryker

In other news, insider Debra King sold 826 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the transaction, the insider owned 6,210 shares in the company, valued at $2,088,423. This represents a 11.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Dylan Crotty sold 441 shares of the firm’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $328.61, for a total transaction of $144,917.01. Following the transaction, the insider owned 6,102 shares in the company, valued at $2,005,178.22. This represents a 6.74% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 351,267 shares of company stock valued at $118,197,701. 4.60% of the stock is currently owned by corporate insiders.

Stryker Stock Down 2.9%

SYK stock traded down $9.81 during mid-day trading on Friday, hitting $325.26. The stock had a trading volume of 3,778,566 shares, compared to its average volume of 2,751,012. Stryker Corporation has a 1-year low of $267.00 and a 1-year high of $389.33. The company has a fifty day moving average of $292.37 and a 200 day moving average of $323.59. The company has a current ratio of 2.18, a quick ratio of 1.30 and a debt-to-equity ratio of 0.60. The stock has a market capitalization of $123.83 billion, a price-to-earnings ratio of 34.64, a PEG ratio of 2.11 and a beta of 0.78.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, October 29th. The medical technology company reported $3.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.55 by ($0.03). The firm had revenue of $6.52 billion for the quarter, compared to analyst estimates of $6.62 billion. Stryker had a net margin of 13.78% and a return on equity of 23.74%. The firm’s quarterly revenue was up 7.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.19 earnings per share. On average, equities analysts expect that Stryker Corporation will post 14.84 EPS for the current fiscal year.

Stryker Profile

Stryker is a medical technology company that develops and sells products and services for healthcare providers. Its offerings include orthopedic implants and surgical equipment, neurotechnology and spine products, and medical and surgical equipment used in hospitals and other care settings.

The company’s products also include patient-handling and emergency medical equipment, as well as instruments and technologies that support surgical procedures. Stryker serves healthcare customers in the United States and internationally.

Founded in 1941 by orthopedic surgeon Dr.